The results showed that the binding of DC-SIGNR to colon cancer cells required the presence of Ca2+, as this binding was inhibited by the addition of a Ca2+ binding chelator (EDTA) (Fig. 1d). Here, CLEC4M is linked to colonic neoplasm.